MAP1LC3A and glycogen storage disease VI: Supporting this broader perspective, a 2021 study showed that gossypol, a clinically approved drug in China, reduces mHTT levels and improves motor function in Huntington’s disease models by stabilizing a VCP-LC3-mHTT ternary complex, thereby promoting autophagic clearance of mHTT (Li et al., 2021).